EXPLORE RESOURCES
FOR USE IN PRACTICE AND WITH PATIENTS

BROWSE OUR LIBRARY OF VIDEOS FROM KEY OPINION LEADERS
IN THE EYE CARE AND EYE HEALTH SPACE

Ophthalmologists share why VYZULTA
works for a variety of their patients

VYZULTA clinical trial results:
See what stood out to these optometrists

See how this once-nightly drop performed in
clinical trials and in practice

Why are low hyperemia and adherence so
important in glaucoma?

See the safety data of this once-nightly drop and
why it can make a difference to ophthalmologists

What matters to an ophthalmologist when
managing glaucoma, and how does this drop deliver?

What’s top of mind for ODs when it
comes to managing glaucoma?

Who is right for VYZULTA? Optometrists
share their opinions

Why are these KOLs excited about this PGA’s
mechanism of action?

Why the VYZULTA dual mechanism of
action may be an option for your glaucoma patients

Discover dual-mechanism IOP reduction
from a novel PGA

Why getting patients access to VYZULTA is
worth it

ODs talk about access and prior
authorization approval experience

  • Ophthalmologists share why VYZULTA
    works     for a variety of their patients

  • VYZULTA clinical trial results:
    See what stood out to these optometrists

  • See how this once-nightly drop performed in
    clinical trials and in practice

  • Why are low hyperemia and adherence so
    important in glaucoma?

  • See the safety data of this once-nightly drop and
    why it can make a difference to ophthalmologists

  • What matters to an ophthalmologist when
    managing glaucoma, and how does this drop deliver?

  • What’s top of mind for ODs when it
    comes to managing glaucoma?

  • Who is right for VYZULTA? Optometrists
    share their opinions

  • Why are these KOLs excited about this PGA’s
    mechanism of action?

  • Why the VYZULTA dual mechanism of
    action may be an option     for your glaucoma patients

  • Discover dual-mechanism IOP reduction
    from a novel PGA

  • Why getting patients access to VYZULTA is
    worth it

  • ODs talk about access and prior
    authorization approval experience

VIEW A COLLECTION OF DOWNLOADABLE AND SHAREABLE RESOURCES DESIGNED FOR EYE CARE PROFESSIONALS

slide share
ABOUT VYZULTA PRESENTATION

An interactive web-based presentation with voiceover that outlines the features, benefits, and safety of VYZULTA

patient adherence
PATIENT ADHERENCE FLASH CARD

Share with patients so they know why it’s important to take VYZULTA once nightly as prescribed

Eye Drop

SIGN UP TO RECEIVE UPDATES AND LEARN MORE ABOUT VYZULTA

All fields are required. You consent to receive communications containing information and educational resources about VYZULTA, as well as other communications from Bausch + Lomb. By submitting your information, you confirm that you have read and agree with the terms of our Privacy Policy and Legal Notice.

INDICATION

VYZULTA® (latanoprostene bunod ophthalmic solution), 0.024% is indicated for the reduction of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.

IMPORTANT SAFETY INFORMATION

  • Increased pigmentation of the iris and periorbital tissue (eyelid) can occur. Iris pigmentation is likely to be permanent
  • Gradual changes to eyelashes, including increased length, increased thickness, and number of eyelashes, may occur. These changes are usually reversible upon treatment discontinuation
  • Use with caution in patients with a history of intraocular inflammation (iritis/uveitis). VYZULTA should generally not be used in patients with active intraocular inflammation
  • Macular edema, including cystoid macular edema, has been reported during treatment with prostaglandin analogs. Use with caution in aphakic patients, in pseudophakic patients with a torn posterior lens capsule, or in patients with known risk factors for macular edema
  • There have been reports of bacterial keratitis associated with the use of multiple-dose containers of topical ophthalmic products that were inadvertently contaminated by patients
  • Contact lenses should be removed prior to the administration of VYZULTA and may be reinserted 15 minutes after administration
  • Most common ocular adverse reactions with incidence ≥2% are conjunctival hyperemia (6%), eye irritation (4%), eye pain (3%), and instillation site pain (2%)
PLEASE SEE FULL PRESCRIBING INFORMATION >

Reference: 1. VYZULTA Prescribing Information. Bausch & Lomb Incorporated.

SEE MORE

INDICATION

VYZULTA® (latanoprostene bunod ophthalmic solution), 0.024% is indicated for the reduction of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.

IMPORTANT SAFETY INFORMATION 
  • Increased pigmentation of the iris and periorbital tissue (eyelid) can occur. Iris pigmentation is likely to be permanent